Termination of a Material Definitive Agreement.

On April 16, 2026, Rigel Pharmaceuticals, Inc. ("Rigel") received written notice from Eli Lilly and Company ("Lilly") of Lilly's election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the "Agreement"), between Rigel and Lilly.

Pursuant to the terms of the Agreement, Lilly has elected to terminate the Agreement in its entirety. The termination will become effective June 15, 2026.


 

The Agreement granted Lilly an exclusive worldwide license to develop and commercialize ocadusertib (previously R552), an investigational, potent and selective receptor interacting serine/threonine protein kinase 1 ("RIPK1") inhibitor, for the treatment of non-central nervous system ("non-CNS") diseases, and additional RIPK1 inhibitors for the treatment of central nervous system ("CNS") diseases. The Agreement also provided for collaboration between the parties on development activities, as well as potential milestone payments and royalties to Rigel.